This week, vaccine manufacturer Moderna revealed that Vinaya Prasad, the top vaccine regulator at the Food and Drug ...
The Food and Drug Administration rejected Moderna’s application for its mRNA-based flu vaccine, the drugmaker said Tuesday ...
Experts say the FDA "moved the goalposts" on Moderna, creating "a destructive precedent that will undermine the future of ...
Florida’s biggest health insurer and others say they will cover all traditional vaccinations through 2026. But governing ...
At issue with Moderna's mRNA flu shot is communication from CBER to Moderna suggesting that the company’s vaccine be compared against a control shot designed more specifically for older people.
PROFIT: The pharmaceutical company is expected to report a loss of $1.02 billion, or $2.54 a share, according to analysts polled by FactSet. That compares with a loss of $1.12 billion, or $2.91 a ...
The move signals an escalation in the agency’s efforts to interfere with established procedures for testing and approving ...
Vinay Prasad, the Trump administration’s top vaccine regulator at the Food and Drug Administration, single-handedly decided to refuse to review Moderna’s mRNA flu vaccine, overruling agency scientists ...
New questions about lung cancer in ‘never-smokers’ As the number of people who smoke has gone down over the decades, those who never smoked have begun to make up a greater proportion of lung cancer ...
The U.S. Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with Nobel Prize-winning mRNA technology, the company announced Tuesday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results